FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043670251> ?p ?o ?g. }

• W3043670251 endingPage "1905" @default.
• W3043670251 startingPage "1905" @default.
• W3043670251 abstract "No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanced non-small cell lung cancer (NSCLC). We conducted a network meta-analysis of four relevant Phase Ⅲ trials to compare the efficacy and safety of Niv+Ipi, pembrolizumab (Pem) plus platinum-based chemotherapy (PBC) (Pem+PBC), Pem, Niv, or PBC using Bayesian analysis. The primary efficacy endpoint was progression-free survival (PFS) in patients with advanced NSCLC with PD-L1 expression ≥1%. The primary safety endpoint was the incidence of Grade 3-5 drug-related adverse events (G3-5AEs). Efficacy and safety were ranked using surface under the cumulative ranking curve (SUCRA). With regard to PFS, Niv+Ipi was inferior to Pem+PBC, and superior to Pem, Niv, or PBC alone. SUCRA ranking showed Pem+PBC had the highest efficacy for PFS, followed by Niv+Ipi, Niv, PBC, and Pem. The safety outcome analysis revealed Niv+Ipi was generally well tolerated compared to existing immunotherapy regimens. These results provide clinical information regarding the efficacy and safety of Niv+Ipi and indicate the possibility of the Niv+Ipi combination as a new therapeutic option in PD-L1-positive advanced NSCLC." @default.
• W3043670251 created "2020-07-23" @default.
• W3043670251 creator A5009618044 @default.
• W3043670251 creator A5016377115 @default.
• W3043670251 creator A5042017809 @default.
• W3043670251 creator A5052452618 @default.
• W3043670251 creator A5058813774 @default.
• W3043670251 creator A5064823132 @default.
• W3043670251 creator A5077367961 @default.
• W3043670251 creator A5084670434 @default.
• W3043670251 creator A5090443937 @default.
• W3043670251 date "2020-07-15" @default.
• W3043670251 modified "2023-10-18" @default.
• W3043670251 title "Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis" @default.
• W3043670251 cites W1493921296 @default.
• W3043670251 cites W1617328014 @default.
• W3043670251 cites W1969888643 @default.
• W3043670251 cites W2005947177 @default.
• W3043670251 cites W2010699829 @default.
• W3043670251 cites W2044200527 @default.
• W3043670251 cites W2094366129 @default.
• W3043670251 cites W2113144077 @default.
• W3043670251 cites W2125776201 @default.
• W3043670251 cites W2127622911 @default.
• W3043670251 cites W2133531206 @default.
• W3043670251 cites W2134143967 @default.
• W3043670251 cites W2135573233 @default.
• W3043670251 cites W2150529573 @default.
• W3043670251 cites W2155654588 @default.
• W3043670251 cites W2239087114 @default.
• W3043670251 cites W2280957887 @default.
• W3043670251 cites W2346278089 @default.
• W3043670251 cites W2516271598 @default.
• W3043670251 cites W2572174216 @default.
• W3043670251 cites W2603440970 @default.
• W3043670251 cites W2616379431 @default.
• W3043670251 cites W2781525129 @default.
• W3043670251 cites W2793945983 @default.
• W3043670251 cites W2794170429 @default.
• W3043670251 cites W2796582438 @default.
• W3043670251 cites W2888420686 @default.
• W3043670251 cites W2889646458 @default.
• W3043670251 cites W2891529252 @default.
• W3043670251 cites W2892640821 @default.
• W3043670251 cites W2897247590 @default.
• W3043670251 cites W2897550585 @default.
• W3043670251 cites W2923325045 @default.
• W3043670251 cites W2925446385 @default.
• W3043670251 cites W2943902312 @default.
• W3043670251 cites W2947183763 @default.
• W3043670251 cites W2947988614 @default.
• W3043670251 cites W2953076879 @default.
• W3043670251 cites W2964471257 @default.
• W3043670251 cites W2970886433 @default.
• W3043670251 cites W2971041600 @default.
• W3043670251 cites W2976744492 @default.
• W3043670251 cites W3003535846 @default.
• W3043670251 cites W3022903699 @default.
• W3043670251 cites W4230177619 @default.
• W3043670251 cites W4243747196 @default.
• W3043670251 cites W4248178819 @default.
• W3043670251 doi "https://doi.org/10.3390/cancers12071905" @default.
• W3043670251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7409193" @default.
• W3043670251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32679702" @default.
• W3043670251 hasPublicationYear "2020" @default.
• W3043670251 type Work @default.
• W3043670251 sameAs 3043670251 @default.
• W3043670251 citedByCount "12" @default.
• W3043670251 countsByYear W30436702512020 @default.
• W3043670251 countsByYear W30436702512021 @default.
• W3043670251 countsByYear W30436702512022 @default.
• W3043670251 countsByYear W30436702512023 @default.
• W3043670251 crossrefType "journal-article" @default.
• W3043670251 hasAuthorship W3043670251A5009618044 @default.
• W3043670251 hasAuthorship W3043670251A5016377115 @default.
• W3043670251 hasAuthorship W3043670251A5042017809 @default.
• W3043670251 hasAuthorship W3043670251A5052452618 @default.
• W3043670251 hasAuthorship W3043670251A5058813774 @default.
• W3043670251 hasAuthorship W3043670251A5064823132 @default.
• W3043670251 hasAuthorship W3043670251A5077367961 @default.
• W3043670251 hasAuthorship W3043670251A5084670434 @default.
• W3043670251 hasAuthorship W3043670251A5090443937 @default.
• W3043670251 hasBestOaLocation W30436702511 @default.
• W3043670251 hasConcept C121608353 @default.
• W3043670251 hasConcept C126322002 @default.
• W3043670251 hasConcept C143998085 @default.
• W3043670251 hasConcept C197934379 @default.
• W3043670251 hasConcept C2776256026 @default.
• W3043670251 hasConcept C2777701055 @default.
• W3043670251 hasConcept C2780030458 @default.
• W3043670251 hasConcept C2780057760 @default.
• W3043670251 hasConcept C2781433595 @default.
• W3043670251 hasConcept C71924100 @default.
• W3043670251 hasConceptScore W3043670251C121608353 @default.
• W3043670251 hasConceptScore W3043670251C126322002 @default.
• W3043670251 hasConceptScore W3043670251C143998085 @default.
• W3043670251 hasConceptScore W3043670251C197934379 @default.
• W3043670251 hasConceptScore W3043670251C2776256026 @default.

• next